TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26333227
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Shugan Yiyang Capsules and oral levocarnitine (Group C)
Study: 16482066
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of NUTRIOSE FB daily
Study: 16482066
Drug: 45 g
Normalized name: SODIUM CHLORIDE 0.045 g in 5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 g of NUTRIOSE FB daily
Study: 16482066
Drug: Placebo (22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (22.5 g of pure maltodextrin)
Study: 16482066
Drug: NUTRIOSE FB
Normalized name: FB-825
DrugBank: FB-825 (DB17598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUTRIOSE FB (both doses)
Study: 9363139
Drug: Intravenous antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotic therapy changed to oral therapy after being afebrile for 16 hours, able to take antibiotics by mouth, and leukocyte count returning towards normal.
Study: 9363139
Drug: Adjunctive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive therapy with nutritional supplements and vitamin C.
Study: 9363139
Drug: Yearly immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yearly immunization with influenza A and B virus vaccine.
Study: 8335810
Drug: Atenolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (5 to 10 mg intravenously followed by 25 to 50 mg orally every 12 h)
Study: 8335810
Drug: Alinidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alinidine (20 to 40 mg intravenously followed by 20 to 40 mg orally every 8 h)
Study: 6831946
Drug: Albuterol (salbutamol)
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (salbutamol)
Study: 15679494
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation with polyethyleneglycol
Study: 1643681
Drug: Stimulation of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation of musculo-cutaneous nerve and one other nerve (G-2)
Study: 1643681
Drug: Stimulation of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation of all four major nerves (G-1)
Study: 1643681
Drug: Stimulation of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation of radial nerve (G-3)
Study: 1643681
Drug: Stimulation of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation of median nerve (G-4)
Study: 1643681
Drug: Stimulation of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation of ulnar nerve (G-5)
Study: 31077026
Drug: Speech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech therapy intervention (SG)
Study: 19078836
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and axillary thermometers
Study: 16536107
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.4 ml (Group S)
Study: 2028533
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dose of metoprolol
Study: 2028533
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dose of metoprolol plus a single dose of placebo
Study: 6689389
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 3 X 20 mg
Study: 6689389
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 3 X 60 mg
Study: 6689389
Drug: Nifedipine 3
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 3 X 20 mg
Study: 6689389
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of Isosorbide dinitrate (ISDN)
Study: 24385406
Drug: Sublingual fentanyl
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual fentanyl (SLF)
Study: 23016517
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel at 20 mg/m(2)
Study: 23016517
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel at 10 mg/m(2) and 15 mg/m(2)
Study: 23016517
Drug: High-dose intensity-modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intensity-modulated radiation therapy (IMRT) at 78 Gy
Study: 19147446
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy with atrial overdrive pacing (CRT + AOP)
Study: 2684804
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g olsalazine
Study: 31358702
Drug: Daily transcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily transcutaneous vagus nerve stimulation (tVNS) for two weeks
Study: 26866103
Drug: TPN with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN with omega 3 fatty acid solution (S-O group)
Study: 26866103
Drug: TPN with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN with glutamine solution (S-D group)
Study: 26866103
Drug: TPN with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN with omega 3 fatty acids solution and glutamine (S-D-O group)
Study: 21384285
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care group (n=20) received standard medical treatment and lifestyle recommendations without additional support.
Study: 15015439
Drug: Jiawei Yupingfeng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiawei Yupingfeng Powder (JYP) administered additionally for 14 days
Study: 15015439
Drug: Conventional western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medicinal therapy
Study: 11440911
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein intake (1.5 g x kg(‐1) x day(‐1))
Study: 11440911
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein intake (0.3 g. kg(‐1) x day(‐1))
Study: 9602576
Drug: Morphine mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine mixed with 1% propofol
Study: 9602576
Drug: Morphine mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine mixed with lvelip
Study: 7800581
Drug: Misoprostol (MI)
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol (MI) 400 mg
Study: 3055791
Drug: Bupivacaine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (2 mg/kg) administered intraperitoneally 10 min before surgery (n = 9)
Study: 3055791
Drug: Saline administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline administered intraperitoneally (n = 10)
Study: 27931552
Drug: Trimetazidine 35mg
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine 35mg sustained release tablet, twice daily
Study: 18096287
Drug: risperidone 6
Normalized name: risperidone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: risperidone 6 mg/day plus propentofylline 900 mg/day (300 mg TDS)
Study: 18096287
Drug: risperidone 6
Normalized name: risperidone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: risperidone 6 mg/day plus placebo
Study: 15483463
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (tenofovir DF) 300 mg once daily
Study: 12428176
Drug: Boron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boron supplementation (11.6 mg boron as 102.6 mg sodium tetraborate decahydrate)
Study: 12428176
Drug: Boron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boron supplementation (11.6 mg boron)
Study: 1685362
Drug: Indapamide (diuretic)
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide (diuretic)
Study: 1685362
Drug: Doxazosin (alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (alpha 1‐blocker)
Study: 1685362
Drug: Slow-release nifedipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release nifedipine (calcium blocker)
Study: 21852659
Drug: After-school health
Approvals — FDA: no, EMA: no, PMDA: no
Description: After-school health education and physical activity program (12 weeks, twice a week)
Study: 17173278
Drug: Paricalcitol (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol (16 microg) with omeprazole (40 mg) (regimen B)
Study: 10682457
Drug: Mifepristone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 10 mg/daily for 3 months
Study: 10682457
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no mifepristone treatment)
Study: 2616602
Drug: Cocaine 40
Normalized name: cocaine 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine 40 mg IV
Study: 22906943
Drug: Adjuvanted vaccine
Normalized name: PIKA-adjuvanted vaccine composition
DrugBank: PIKA rabies vaccine (DB17963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted vaccine (3.8 µg or 7.5 µg HA)
Study: 22906943
Drug: Non-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted vaccine (15 µg HA)
Study: 22906943
Drug: Adjuvanted vaccine
Normalized name: PIKA-adjuvanted vaccine composition
DrugBank: PIKA rabies vaccine (DB17963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted vaccine (1.9 µg or 3.8 µg HA)
Study: 22906943
Drug: Non-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted vaccine (7.5 µg HA)
Study: 17573885
Drug: Pimecrolimus cream
Normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimecrolimus cream 1% (twice daily) + Fluticasone propionate cream 0.05% (once daily)
Study: 17573885
Drug: Vehicle (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (twice daily) + Fluticasone propionate cream 0.05% (once daily)
Study: 11842880
Drug: 300mg S-PS
Normalized name: florfenicol
DrugBank: Florfenicol (DB11413)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg S-PS daily
Study: 11842880
Drug: 600mg S-PS
Normalized name: brewer's yeast 600 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg S-PS daily
Study: 25742205
Drug: Acamprosate (1,998
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (1,998 mg/d orally)
Study: 23108604
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg/tadalafil 5 mg
Study: 23108604
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg/placebo
Study: 14737726
Drug: Radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine therapy with (131)I at doses ranging from 5‐200 mCi
Study: 16227794
Drug: Nevirapine (NVP)
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine (NVP) administered to mothers at labor onset and to infants within 72 hours of birth.
Study: 16227794
Drug: Nevirapine (NVP)
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine (NVP) administered to infants < 4 hours after birth.
Study: 16227794
Drug: Nevirapine (NVP)
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine (NVP) administered to mothers within 24 hours of delivery.
Study: 16227794
Drug: Nevirapine (NVP)
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine (NVP) administered to infants within 48 hours after delivery.
Study: 10352203
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L exchange volume
Study: 10352203
Drug: 2.5 L
Normalized name: ALCOHOL 1.875 L in 2.5 L TOPICAL LIQUID [EXIHUAN Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 L exchange volume
Study: 10352203
Drug: 3 L
Normalized name: D3 Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 L exchange volume
Study: 12429243
Drug: Povidone-iodine 1.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Povidone-iodine 1.25% ophthalmic solution
Study: 27984024
Drug: Topical antibiotics
Normalized name: Tetracycline and derivatives, topical antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antibiotics (neomycin-polymyxin B-gramicidin in the Philippines; ciprofloxacin 0.3% in India)
Study: 25471330
Drug: Ranibizumab 0.3
Normalized name: RANIBIZUMAB 0.3MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.3 mg plus single standard verteporfin PDT
Study: 25471330
Drug: Ranibizumab 0.3
Normalized name: RANIBIZUMAB 0.3MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.3 mg plus sham PDT
Study: 19805698
Drug: Care management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care management plus telephone psychotherapy intervention (8-session structured cognitive behavioral therapy program with up to 4 additional calls)
Study: 17173213
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine gluconate washes and 2% mupirocin ointment intranasally, with oral rifampin and doxycycline for 7 days
Study: 17173213
Drug: Decolonization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decolonization therapy
Study: 11486310
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy (HDT) supported with autologous stem cells
Study: 11486310
Drug: Melphalan 200
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan 200 mg/m(2)
Study: 9706915
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg x kg(‐1) x h(‐1))
Study: 9706915
Drug: Sufentanil (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (0.25 microg x kg(‐1) x h(‐1) with bolus midazolam 2 mg)
Study: 21950196
Drug: Melatonin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (20 mg/day) for 12 weeks
Study: 21950196
Drug: Melatonin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (20 mg/day)
Study: 16521172
Drug: Single-lumen tube
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-lumen tube with free drainage and 4-hourly aspiration
Study: 10630440
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution plus Lactobacillus GG (at least 10(10) CFU/250 ml)
Study: 10630440
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution plus placebo
Study: 1531487
Drug: Treatment by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment by general practitioner (GP)
Study: 1531487
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (detuned ultrasound and detuned short wave diathermy)
Study: 29691617
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for Achilles tendon rupture
Study: 29691617
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment for Achilles tendon rupture
Study: 27879147
Drug: Novel agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel agent induction regimens (including proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs)) prior to HDM/SCT
Study: 27879147
Drug: No novel
Approvals — FDA: no, EMA: no, PMDA: no
Description: No novel agent induction regimens prior to HDM/SCT
Study: 27879147
Drug: Novel agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel agent induction regimens (including PIs and IMiDs) prior to HDM/SCT
Study: 24939677
Drug: Infliximab ≤3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab ≤3 mg/kg
Study: 24939677
Drug: Infliximab 3-5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 3-5 mg/kg
Study: 24939677
Drug: Infliximab ≥5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab ≥5 mg/kg
Study: 24939677
Drug: Infliximab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (all doses)
Study: 23126252
Drug: Dalcetrapib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib (600 mg daily)
Study: 20483049
Drug: Infliximab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (3 mg/kg) administered at week 0, 2, 6, and 14 along with stable dose of methotrexate
Study: 12466380
Drug: Pegvisomant (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvisomant (1 mg/kg sc)
Study: 7796154
Drug: Caffeine 200
Normalized name: caffeine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 200 mg administered at 07.10 h
Study: 1710673
Drug: Low-dose chemotherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance
Study: 6115732
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg propranolol
Study: 6115732
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg sotalol
Study: 31403867
Drug: Toripalimab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab (1 or 3 mg/kg via intravenous infusion every 2 weeks) + Axitinib (5 mg orally twice a day)
Study: 19918967
Drug: Apilimod mesylate
Normalized name: mesylate
DrugBank: Apilimod (DB05611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apilimod mesylate 50 mg daily
Study: 19918967
Drug: Apilimod mesylate
Normalized name: mesylate
DrugBank: Apilimod (DB05611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apilimod mesylate 100 mg daily
Study: 30482055
Drug: KiSS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: KiSS treatment (multicomponent six-session program including CBT-I, hypnotherapy, and imaginations)
Study: 31178421
Drug: Inhaled 7%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled 7% hypertonic saline nebulised twice daily for 48 weeks
Study: 31178421
Drug: 0.9% isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% isotonic saline nebulised twice daily for 48 weeks
Study: 29328838
Drug: Dronedarone 400mg
Normalized name: DRONEDARONE 400MG TAB
DrugBank: Dronedarone (DB04855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dronedarone 400mg orally twice daily, commencing three days prior to surgery
Study: 24005882
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) (808 nm; 100 mW; 35.7 W/cm(2), 357.14 J/cm(2) per point, energy of 1 J per point applied for 10 s on four points of the biceps brachii belly of each arm)
Study: 23007025
Drug: Biocompatible PD
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biocompatible PD solution (Balance®, Fresenius; LS)
Study: 23007025
Drug: Conventional PD
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional PD solution (CAPD/DPCA®, Fresenius; CS)
Study: 17855735
Drug: Epidural mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural mepivacaine (0.15 ml kg(‐1) bolus of 2% mepivacaine, followed by 0.1 ml kg(‐1) h(‐1))
Study: 17855735
Drug: Neostigmine (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.04 mg kg(‐1) at 25% recovery of the first twitch of TOF)
Study: 10753985
Drug: Intraventricular urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraventricular urokinase treatment
Study: 9816086
Drug: IFN‐gamma at
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐gamma at dose levels ranging from 0.01 to 0.90 mg/m2, administered as a 1‐h i.v. infusion three times per week for at least 8 weeks or until progressive disease.
Study: 6547461
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of STs and RASTs
Study: 30611598
Drug: Comprehensive oral
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive oral management protocol including spacers, pilocarpine hydrochloride, and topical dexamethasone ointment for oral mucositis
Study: 30611598
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving only oral care
Study: 30428863
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care with supervised foot-ankle exercises (twice a week for 12 weeks) and remotely supervised exercises for a year
Study: 20935397
Drug: Oral doxophylline
Normalized name: proxyphylline
DrugBank: Proxyphylline (DB13449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doxophylline (400 mg/day)
Study: 20935397
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (400 mcg)
Study: 1531285
Drug: Foscarnet (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet (40 mg/kg every 8 or 12 hours)
Study: 1531285
Drug: Acyclovir maintenance
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir maintenance following foscarnet induction therapy
Study: 31423712
Drug: High-intensity care
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity care (up-titration of oral HF medications including beta-blockers, ACE inhibitors or ARBs, and MRAs)
Study: 29417902
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (5 × 10^7 haMSCs)
Study: 29417902
Drug: Mid-dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-dose group (2 × 10^7 haMSCs)
Study: 29417902
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (1 × 10^7 haMSCs)
Study: 18538110
Drug: Depot antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot antipsychotic drugs (DA)